Rebecca S Kristeleit (Rebecca Kristeleit)

Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 25

Top Topics

Acute Myeloid Leukemia

Advanced Cancer

Epidermal Growth Factor Receptor

Dna Damage Response

Top Venues

British journal of cancer

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Rebecca S Kristeleit, Alexandra Leary, Ana Oaknin, Andres Redondo, Angela George, Stephen Chui, Aicha Seiller, Mario Liste-Hermoso, Jenna Willis, Colby S Shemesh, Jim Xiao, Kevin K Lin, Luciana Molinero, Yinghui Guan, Isabelle L Ray-Coquard, Linda R Mileshkin
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. British journal of cancer 131 (5) (2024)
Rebecca S Kristeleit, Alexandra Leary, Ana Oaknin, Andres Redondo, Angela George, Stephen Chui, Aicha Seiller, Mario Liste-Hermoso, Jenna Willis, Colby S Shemesh, Jim Xiao, Kevin K Lin, Luciana Molinero, Yinghui Guan, Isabelle L Ray-Coquard, Linda R Mileshkin
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers. British journal of cancer (2024)
Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain A McNeish, Rosalind M Glasspool, Marcia Hall, Rene Roux, Agnieszka Michael, Andrew Clamp, Gordon Jayson, Rebecca S Kristeleit, Susana Banerjee, Anita Mansouri
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. British journal of cancer 130 (6) (2024)
Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain A McNeish, Rosalind M Glasspool, Marcia Hall, Rene Roux, Agnieszka Michael, Andrew Clamp, Gordon Jayson, Rebecca S Kristeleit, Susana Banerjee, Anita Mansouri
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. British journal of cancer 130 (6) (2024)
Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain A McNeish, Rosalind M Glasspool, Marcia Hall, Rene Roux, Agnieszka Michael, Andrew Clamp, Gordon Jayson, Rebecca S Kristeleit, Susana Banerjee, Anita Mansouri
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. British journal of cancer (2024)
Shibani Nicum, Naomi McGregor, Rachel Austin, Linda Collins, Susan Dutton, Iain A McNeish, Rosalind M Glasspool, Marcia Hall, Rene Roux, Agnieszka Michael, Andrew Clamp, Gordon Jayson, Rebecca S Kristeleit, Susana Banerjee, Anita Mansouri
Results of a randomised Phase II trial of olaparib, chemotherapy or olaparib and cediranib in patients with platinum-resistant ovarian cancer. British journal of cancer 130 (6) (2024)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Curigliano Giuseppe, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A Gelmon, Erica Stringer-Reasor, Ulka N Vaishampayan, Mark Ross Middleton, Anthony J Olszanski, Hope S Rugo, Kenneth A Kern, Nuzhat Pathan, Rachelle Perea, Kristen J Pierce, Sarah C Mutka, Zev A Wainberg
Correction to: A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British journal of cancer (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Rebecca S Kristeleit, Ruth Plummer, Robert Jones, Louise Carter, Sarah P Blagden, Debashis Sarker, Tobias Arkenau, Thomas R Jeffry Evans, Sarah Danson, Stefan N Symeonides, Gareth J Veal, Barbara J Klencke, Mark M Kowalski, Udai Banerji
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer. British journal of cancer (2023)
Ana Oaknin, Bhavana Pothuri, Lucy Gilbert, Renaud Sabatier, Jubilee Brown, Sharad A Ghamande, Cara A Mathews, David M O'Malley, Rebecca S Kristeleit, Valentina Boni, Adriano Gravina, Susana Banerjee, Rowan E Miller, Joanna Pikiel, Mansoor Raza Mirza, Ninad Dewal, Grace Antony, Yuping Dong, Eleftherios Zografos, Jennifer T Veneris, Sarah A Cook
Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
Jason John Luke, Marwan Fakih, Charles Schneider, E Gabriela Chiorean, Johanna Bendell, Rebecca S Kristeleit, Razelle Kurzrock, Sarah P Blagden, Irene Brana, Laura W Goff, Kevin O'Hayer, Ryan Geschwindt, Michael Smith, Feng Zhou, Aung Naing
Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors. British journal of cancer (2023)
James F Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca S Kristeleit, Rowan E Miller, Gareth J Veal, Christopher J Corrigan, Stephen J Till, Alessandro Massimo Gianni, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary J Doherty, Hannah J Gould, Giulia Pellizzari, Mano Nakamura, Kristina M Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah E Pinder, Heather J Bax, Debra H Josephs, Sophia N Karagiannis
Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial. Nature communications 14 (1) (2023)
Bradley J Monk, Christine Parkinson, Myong Cheol Lim, David M O'Malley, Ana Oaknin, Michelle K Wilson, Robert L Coleman, Domenica Lorusso, Paul Bessette, Sharad Ghamande, Athina Christopoulou, Diane Provencher, Emily Prendergast, Fuat Demirkiran, Olga Mikheeva, Oladapo O Yeku, Anita Chudecka-Glaz, Michael Schenker, Ramey D Littell, Tamar Safra, Hung-Hsueh Chou, Mark A Morgan, Vít Drochýtek, Joyce N Barlin, Toon Van Gorp, Frederick Rand Ueland, Gabriel Lindahl, Charles Anderson, Dearbhaile C Collins, Kathleen M Moore, Frederic Marmé, Shannon Neville Westin, Iain A McNeish, Danny Shih, Kevin K Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca S Kristeleit
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (34) (2022)
Robert Jones, Ruth Plummer, Victor Moreno, Louise Carter, Desamparados Roda, Elena Garralda, Rebecca S Kristeleit, Debashis Sarker, Hendrick-Tobias Arkenau, Patricia Roxburgh, Harriet Sarah Walter, Sarah P Blagden, Alan Anthony, Barbara J Klencke, Mark M Kowalski, Udai Banerji
A Phase I/II Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Low-Dose Gemcitabine in Patients with Advanced Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Rebecca S Kristeleit, Yvette Drew, Amit M Oza, Susan M Domchek, Susana Banerjee, Rosalind M Glasspool, Judith Balmaña, Lee-May Chen, Manish R Patel, Howard A Burris, Tamar Safra, Jennifer Borrow, Kevin K Lin, Sandra Goble, Lara Maloney, Ronnie Shapira-Frommer
Efficacy and safety of rucaparib treatment in patients with BRCA-mutated, relapsed ovarian cancer: final results from Study 10. British journal of cancer (2022)
Curigliano Giuseppe, Geoffrey I Shapiro, Rebecca S Kristeleit, Albiruni R Abdul Razak, Stephen Leong, Maria Alsina, Antonio Giordano, Karen A Gelmon, Erica Stringer-Reasor, Ulka N Vaishampayan, Mark Ross Middleton, Anthony J Olszanski, Hope S Rugo, Kenneth A Kern, Nuzhat Pathan, Rachelle Perea, Kristen J Pierce, Sarah C Mutka, Zev A Wainberg
A Phase 1B open-label study of gedatolisib (PF-05212384) in combination with other anti-tumour agents for patients with advanced solid tumours and triple-negative breast cancer. British journal of cancer (2022)
Beth Russell, Charlotte Moss, Eirini Tsotra, Charalampos Gousis, Debra Josephs, Deborah Enting, Christina Karampera, Muhammad Khan, Jose Roca, Ailsa Sita-Lumsden, Kasia Owczarczyk, Harriet Wylie, Anna Haire, Daniel Smith, Kamarul Zaki, Angela Swampillai, Mary Lei, Vishal Manik, Vasiliki Michalarea, Rebecca S Kristeleit, Anca Mera, Elinor Sawyer, Lucy Flanders, Irene De Francesco, Sophie Papa, Paul Ross, James Spicer, Bill Dann, Vikash Jogia, Nisha Shaunak, Hartmut Kristeleit, Anne Rigg, Ana Montes, Mieke Van Hemelrijck, Saoirse Dolly
The Impact of COVID-19 on the Delivery of Systemic Anti-Cancer Treatment at Guy's Cancer Centre. Cancers 14 (2) (2022)
Michael-John Devlin, Rowan E Miller, Florian Laforets, Panoraia Kotantaki, Dale W Garsed, Rebecca S Kristeleit, David D L Bowtell, Jacqueline McDermott, Eleni Maniati, Frances R Balkwill
The Tumor Microenvironment of Clear-Cell Ovarian Cancer. Cancer immunology research 10 (11) (2022)
Bradley J Monk, Keiichi Fujiwara, David M O'Malley, Robert L Coleman, Iain A McNeish, Kevin K Lin, Stephanie Hume, Rebecca S Kristeleit
Reply to C. Marchetti et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Heather J Bax, Jitesh Chauhan, Chara Stavraka, Aida Santaolalla, Gabriel Osborn, Atousa Khiabany, Melanie Grandits, Jacobo López-Abente, Lais C G F Palhares, Charleen Chan Wah Hak, Alexandra Robinson, Amy Pope, Natalie Woodman, Cristina Naceur-Lombardelli, Sadek Malas, Jack E M Coumbe, Mano Nakamura, Roman Laddach, Silvia Mele, Silvia Crescioli, Anna M Black, Sara Lombardi, Silvana Canevari, Mariangela Figini, Ahmad Sayasneh, Sophia Tsoka, Kevin FitzGerald, Cheryl Gillett, Sarah E Pinder, Mieke Van Hemelrijck, Rebecca S Kristeleit, Sharmistha Ghosh, Ana Montes, James Spicer, Sophia N Karagiannis, Debra H Josephs
Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. British journal of cancer (2022)
Elizabeth M Swisher, Tanya T Kwan, Amit M Oza, Anna V Tinker, Isabelle L Ray-Coquard, Ana Oaknin, Robert L Coleman, Carol Aghajanian, Gottfried E Konecny, David M O'Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-May Chen, Andrea E Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H Kaufmann, Julia A Elvin, Douglas I Lin, Setsuko K Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L Scott, Kevin K Lin, Iain A McNeish
Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nature communications 12 (1) (2021)
James F Spicer, Aurélien Marabelle, Jean-Francois Baurain, Nina Louise Jebsen, Dag Erik Jøssang, Ahmad Awada, Rebecca S Kristeleit, Delphine Loirat, George Lazaridis, Christiane Jungels, Paal Brunsvig, Berit Nicolaisen, Andrew Saunders, Hamina Patel, Jerome Galon, Fabienne Hermitte, Ketil André Camilio, Brynjar Mauseth, Vibeke Sundvold, Baldur Sveinbjørnsson, Øystein Rekdal
Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Timothy Anthony Yap, Rebecca S Kristeleit, Vasiliki Michalarea, Stephen J Pettitt, Joline S J Lim, Suzanne Carreira, Desamparados Roda, Rowan Miller, Ruth Riisnaes, Susana Miranda, Ines Figueiredo, Daniel Nava Rodrigues, Sarah Ward, Ruth Matthews, Mona Parmar, Alison Turner, Nina Tunariu, Neha Chopra, Heidrun Gevensleben, Nicholas C Turner, Ruth Ruddle, Florence I Raynaud, Shaun Decordova, Karen E Swales, Laura Finneran, Emma C Hall, Paul Rugman, Justin P O Lindemann, Andrew Foxley, Christopher J Lord, Udai Banerji, Ruth Plummer, Bristi Basu, Juanita S Lopez, Yvette Drew, Johann S de Bono
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers. Cancer discovery 10 (10) (2020)